

N THE UNITED STATES PATENT AND TRADEMARK OFFICE

pplication of:

Finklestein, S. et al.

Application No:

10/605,456

Filed:

September 30, 2003

For:

Promoting Recovery from Damage to

the Central Nervous System

Examiner:

Not Yet Assigned

Art Unit:

1632

Confirmation No.: 2455

Attorney Document No. CBA-003.02

CERTIFICATE OF FIRST CLASS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on January 6, 2004.

Shirine Darvish

<u>INFORMATION DISCLOSURE STATEMENT</u> <u>UNDER 37 C.F.R. § 1.97(b)(3)</u>

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The above-referenced application is a continuation of USSN 09/642,277, which was filed on August 18, 2000. Accordingly, Applicants request that all documents made of record in USSN 09/642,277 be made of record in the above-referenced application. Copies are submitted herewith of Forms PTO 1449 filed May 14, 2001 and January 10, 2003.

In accordance with 37 CFR 1.98(d)(2), no copies of the references cited in these Forms PTO 1449 are enclosed herewith, because the Information Disclosure Statements filed in USSN 09/642,277 complied with 37 CFR 1.98 sections (a) through (c).

In addition, a further Form PTO/SB/08a is filed listing references cited by the Examiner

in USSN 09/642,277. Copies of the documents are not submitted because they were all made of

record in USSN 09/642,277.

Applicants respectfully request that the Examiner consider the listed documents and

indicate that they were considered by making appropriate notations on the attached Form

PTO/SB/08a.

This submission does not represent that a search has been made or that no better art

exists. Nor does it constitute an admission that the listed documents are material or constitute

"prior art." If the Examiner applies the cited documents as prior art against any claim in the

application and Applicants determine that the cited documents do not constitute "prior art" under

United States law, Applicants reserve the right to present to the Office the relevant facts and law

regarding the appropriate status of said document. Applicants further reserve the right to take

appropriate action to establish the patentability of the disclosed invention over the listed

documents, should one or more of the cited references be applied against the claims of the

present application.

This Information Disclosure Statement is being filed before the mailing of a first Office

By:

Action on the merits; therefore, no fees are due. However, the Commissioner is authorized to

credit any overpayment or charge any deficiencies to/from our Deposit Account, No. 06-1448.

Respectfully submitted,

Scott E. Kamholz

Agent for Applicants

Reg. No. 48,543

FOLEY HOAG LLP

Date: __January 6, 2004

Customer No.: 25181

Patent Group Foley Hoag LLP 155 Seaport Blvd Boston MA 02210-2600

Voice: (617) 832-1230

-2-20/574261.1

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known						
Application Number	10/605,456					
Filing Date	September 30, 2003					
First Named Inventor	Finklestein, Seth					
Art Unit	1632					
Examiner Name	Not Yet Known					
Attorney Docket Number	CBA-003.02					

_			U.S. PATENT [DOCUMENTS	
Examiner Cite No.	Cite	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevan Passages or Relevant Figures Appear
	No.1	Number - Kind Code ² (if known)	MM-DD-YYYY		
		US-			
		US-	-		
		US-			
		US-			
		US-	-		
		US-			· · · · · · · · · · · · · · · · · · ·
		US-			
	1	US-			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite	Foreign Patent Document	D. Atlantin	Name of Patentee or	Pages, Columns, Lines,		
	No.1	Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	Т ⁶	
	N	FR 2 642 086	07-1990	Caput et al.			
	0	WO 00/71715	11-2000	Rosen et al.			
.,	Р	EP 86117257.5	06-1987	Moscatelli et al.	1		
	Q	EP 89101162.9	08/1989	Senoo et al.			

	_	
Examiner Signature	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Nicht of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b(08-03) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

TO AD Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known Application Number 10/605,456 Filing Date September 30, 2003 First Named Inventor Finkelstein, Seth Art Unit 1632 Examiner Name Not Yet Known

(Use as many sheets as necessary)

2 Sheet 2 of Attorney Docket Number CBA-003.02

	,	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	υ	Barker et al., Neural transplantation therapies for Parkinson's and Huntington's Diseases, 2001, DDT, Vol. 6 pp. 575-582	
	v	Kmiec, Investigators have been searching for ways to add corrective genes to cells harboring defective genes, 1999, AMERICAN SCIENTIST, Vol. 87, pp. 240-247	
	w	Daughaday et al., Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations, 1989, ENDOCRINE REVIEWS, Vol. 10, pp. 68-91	
·			
		-	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant:

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Docket Number (Optional) Application Number IN AN APPLICATION
(Use several sheets if necessary) CBA-003.01 09/642,277 Applicant JAH 1 3 2003 Finklestein et al. JAN 0 9 2004 Filing Date Group Art Unit August 18, 2000 1636 U.S. PATENT DOCUMENTS FILING DATE **WIMPERNI** DOCUMENT DATE INITIAL NAME CLASS **SUBCLASS** IF APPROPRIATE Oct. 6, 5,817,773 Wilson et al. 530 399 121 1998 **HECEIVED** JAN 1 6 2003 <u>TFCH CENITER 1600/2900</u> FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DATE Translation COUNTRY **CLASS** SUBCLASS YES МО 25 BX WO 97/34618 September PCT 1997 23 BY WO 00 69448 PCT November 2000 **OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages Etc.) Dinsmore, J. et al., "Embryonic Stem Cells Differentiated In Vitro As A Novel Source Of Cells For Transplantation", Cell Transplantation USA 5(2): 131-143 (1996). ΒZ Kennedy, T.E. et al., "Netrins Are Diffusible Chemotropic Factors For commissural Axons In The Embryonic Spinal Cord", Cell USA 78: 425-435 (August 1994). Marciniak, A. et al., "Neural Stem Cells, In Combination With Basic Fibro-Blast Growth Factor (bFGF), May Represent A Treatment For Stroke", Experimental Neurology 164(2): 444 (August 2000). CB Strömberg, M. et al, "Chronic Implants Of Chromaffin Tissue Into The Dopamine-Denervated Striatum. Effects of NGF On Graft Survival, Fiber Growth And Rotational Behavior", Exp Brain Res 60: 335-349 (1985). CC International Search Report, PCT Pub. No. WO 01/12236, filed August 18, 2000. CD

Double 3/4/03

20/532646.1

Ē

					f	tpolican	+	Sheet Pag	ge l of 3
	(N A)	N DISCLOSURE CITA N APPLICATION E	\	CB	cket Number (Optional) P A-003.01	09/6	lication Numb 542,277		
, (U	se sev	eral shepts if necessary)	JC184	Fin	klestein et al. JAN 0 9 2004	3	up Art Unit		
		MAY 1 7 200	700 J	Au	ng Date gust 18, 2000 S. PATENT DOCUMENES	164	\$ 1636		•
XAMINER INITIAL	_ E	OCUMENT NOTABLE NA			NAME	CLASS	SUBCLASS	FILING DA	
ssl	AA	5,175,103	Dec. 29		Lee et al.	435	172.3	Oct. 21, 1	991
	AB	5,270,191	Dec 14, 1	993	McKay et al.	435	172.3	May 12, 1	992
	AC	5,733,871	March 3		Alps et al.	514	12	March 16,	1995
	AD	5,750,376	May 12 1998		Weiss et al.	435	69.52	June 7, 19	95
	AE	5,753,506	May 19		Johe .	435	377	September 25	, 1996
	AF	5,840,580	Novemb 24, 199		Terstappen et al.	435	372	May 14, 1	997
	AG	5,914,108	June 22 1999		Tsukamoto et al.	424	93.7	June 6, 19	95
	AH	5,958,767	Sep. 28 1999		Snyder et al.	435	368	Aug. 14, 1	998
V	ΑI	5,968,829	October 1999	19,	Carpenter	435	467	September 5	1997
				OR	EIGN PATENT DOCUMENT	S	<u> </u>		
	D	OCUMENT NUMBER	DATE	3	COUNTRY	CLASS	SUBCLASS	Translation YES	on NO
ssl	AJ	WO 94/03199	17 Febru 1994	агу	PCT				_
	AK	WO 95/24469	14 Septemb 1995		РСТ		R	ECE	VE
	AL	WO 96/15224	23 May 1	996	PCT	-		MAY 2.1	2001
V	AM	WO 00/00588	6 Januar 2000	гу	PCT	-	TECH	CENTER 1	-
SSP	AN		HER DO	of Po	lymer Encapsulated Neurotransmitter Secreti		or, Title, Date, Pe	rtinent Pages Etc	:.)
	AO	Andersson, Candace et al., "Transplantation of Cultured Type 1 Astrocyte Cell Suspensions into Young, Adult and Aged Rat cortex: Cell Migration and Survival", Int. J. Devl. Neuroscience 11(5): 555-568 (1993).							
	AP	Andsberg, Gunner ET al., "Amelioration of Ischaemia-Induced Neuronal Death in the Rat Striatum by NGF-Secreting Neural Stem Cells", European Journal of Neuroscience 10: 2026-2036 (1998).							
	AQ	Bavetta, Seb et al., "The l Regeneration", Experime	Effects of Fintal Neurole	K.506 ogy 1.5	on Dorsal Column Axons Following Spinal (58: 382-393 (1999).	Cord Injury in Adu	lt Rats: Neuroprot	ection and Local	
$\overline{\downarrow}$	AR	Bhatia, Mickie et al., "A 1 1045 (September 1998).	Newly Disc	overe	d Class of Human Hematopoietic Cells with S	SCID-Repopulating	g Activity", Natur	e Medicine 4(9):	1038-
•	E	xaminer:	Sit	~	Pappu	Date:	05/0	8/02	

20/456263.1

Examiner: Sita Pappu

Date: 05/08/02

CIT CENTED 1000/2000

Form PTO-1449	N DISCLOSURE OF Application Number ORA-003 01 ORA-003 01
↓ IN A	N APPLICATION CHARGE Applicant
(Use ser	Finklestein et al. JAN 0 9 2004 75
•	Filing Date August 18, 2000 Filing Date August 18, 2000 Filing Date August 18, 2000
es 0	Mehler, Mark F. et al., "Cytolene Regulation of Neuronal Differentiation of Hippocampal Progenitor Cells", Nature 362: 62-64 (4 March 1993).
SSP BI	TRADEMA
	Minorlin Shari et al. "A Naval Five Transmembrane Hemotomoietic Stars Cell Antigan: Isolation Characterization and Malacular Claring"
BK	Miraglia, Sheri et al., "A Novel Five-Transmembrane Hematopoietic Stem Cell Antigen: Isolation, Characterization and Molecular Cloning", Blood 90(12): 5013-5021 (December 15, 1997).
4	Park, Kook In et al., "Transplantation of Neural Progenitor and Stem Cells: Developmental Insights May Suggest New Therapies for Spinal Cord and Other CNS Dysfunction" Journal of Neurotrauma 16(8): 675-687 (1999).
	and Other City Dystunction Journal of recursivating 10(6). 073-067 (1993).
5 3 1	Ray, Jasodhara et al., "A 10-Amino Acid Sequence of Fibroblast Growth Factor 2 is Sufficient for its Mitogenic Activity on Neural Progenitor
	Calle? Deen Not Acad Co. 110 A 04, 7047 7052 (Iven 1007)
	P. F. W. J. W. J. W. J. G. W. J. G. W. J. R. J.
± ± ±	Ren, JingMei, et al., "Time Window of Intracistemal Osteogenic Protein-1 in Enhancing Functional Recovery after Stroke", Neuropharmacology 39: 860-865 (2000).
2001/200	Snyder, Evan Y. et al., "Multipotent Neural Precursors can Differentiate Toward Replacement of Neurons Undergoing Targeted Apoptotic Degeneration in Adult Mouse Neocortex", Proc. Natl. Acad. Sci. USA 94: 11663-11668 (October 1997).
BO	Degeneration in Adult Mouse Neocottex , Proc. Natl. Acad. Sci. USA 94: 11005-11008 (October 1997).
	Stroemer, R. Paul PhD et al., "Enhanced Neocortical Neural Sprouting, Synaptogenesis, and Behavioral Recovery with D-Amphetamine Therapy
BP	after Neconstical Infantion in Pata" Strake 20, 2291 2205 (1009)
ВО	Tamura, A. et al., "Focal Cerebral Ischaemia in the Rat:1. Description of Technique and Early Neuropathological Consequences Following Middle Cerebral Artery Occlusion", Journal of Cerebral Blood Flow and Metabolism 1: 53-60 (1981).
	Thomson, James A. et al., "Embryonic Stem Cell Lines Derived from Human Blastocysts", Science 282: 1145-1147 (6 November 1998).
BR	
	Van Vactor, David et al., "Neural Development: The Semantics of Axon Guidance", Current Biology 9: R201-R204 (1999).
BS	
ВТ	Villa, Ana et al., "Establishment and Properties of a Growth Factor-Dependant, Perpetual Neural Stem Cell Line from the Human CNS", Experimental Neurology 161: 67-84 (2000).
	·
	Withers, G. S. et al., "Bone Morphogenetic Protein-7 Enhances Dendritic Growth and Receptivity to Innervation in Cultured Hippocampal Neurons", European Journal of Neuroscience 12: 106-116 (2000).
BU	Neurons , European Journal of Neuroscience 12. 100-110 (2000).
	Yrjanheikki, Juha et al., "Tetracyclines Inhibit Microglial Activation and are Neuroprotective in Global Brain Ischemia", Proc. Natl. Acad. Sci.
BV	IIGA 05: 15760 15774 (December 1009)
W	
	·
ļ	
	·